Trials / Completed
CompletedNCT00242229
Study Evaluating DVS-233 SR in Elderly Outpatients With Major Depressive Disorder
A 6 Month, Open-Label Evaluation of the Long-Term Safety of DVS-233 SR in Elderly Outpatients With Major Depressive Disorder (MDD)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer · Industry
- Sex
- All
- Age
- 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the overall safety and tolerability profile of two dose levels of DVS-233 SR during 6 months of open-label treatment in elderly outpatients with major depressive disorder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DVS-233 SR |
Timeline
- Start date
- 2004-10-01
- Primary completion
- 2005-10-01
- Completion
- 2005-10-01
- First posted
- 2005-10-19
- Last updated
- 2009-08-19
Source: ClinicalTrials.gov record NCT00242229. Inclusion in this directory is not an endorsement.